Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum pharmacokinetics of Caspofungin in patients with liver failure
2012-004031-23Phase 4Completed
- Sponsor
- Erasmus Hospital
- Start
- Feb 2013
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of caspofungin in invasive aspergillosis (IA), hepatic failure, alcoholic hepatitis (AH) and 1 more, sponsored by Erasmus Hospital. Primary endpoint: Population pharmacokinetics of caspofungin. Started Feb 2013; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive aspergillosis (IA)hepatic failurealcoholic hepatitis (AH)Cirrhosis
Beyond the preview
Go deeper on 2012-004031-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004031-23.